ArticleBreast cancer research and treatment2025
Effects of intermittent discontinuation cyclin-dependent kinase inhibitors on metastatic breast cancer during Lebanon's economic crisis.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study examines the intermittent discontinuation of palbociclib based on its availability and its clinical outcomes during the Lebanese economic crisis in patients with metastatic Breast Cancer (BC) HR+ between the years 2019 and 2023.
methodsThis study carries out a retrospective analysis on 46 patients treated with palbociclib - Letrozole during the years 2019 and 2023 in Lebanon. It used descriptive tables and figures to summarize demographic, clinical, and outcome characteristics. It analyzed the data using Student T test for parametric variables, Wilcoxon and Kruskal-Wallis tests for non-parametric variables, and Chi-squared and Fisher tests for qualitative variables. Pearson's correlation and regression models were used to associate between the intermittent administration of palbociclib and its clinical outcomes.
resultsOur sample had a mean age of 59.33 +/-13.27 years. 87% had ductal carcinomas and 13% had lobular carcinomas. 52.2% of patients had treatment for their metastases prior to palbociclib, and a discontinuation was observed in 63.1 %. Intermittent discontinuation is associated with advanced age (p=0.048) and statistically reduces PFS (p=0.026). The intermittent drug intake also affects PFS (p=0.03) but has no effect on the disease progression.
conclusionThis study is the only research in the world focused on intermittent intake of palbociclib. The intermittent discontinuation of palbociclib is influenced by age and affects the PFS. These results highlight the significance of adherence and protocol compliance.
Indexed as
Identifiers
40932628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.